Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Podophyllum resin

×

Overview

What is Podocon 25?

Podocon-25® is composed of Podophyllin (Podophyllum Resin, American) 25% in Benzoin Tincture. Podophyllum Resin is the powdered mixture of resins removed from the May apple or Mandrake ( ), a perennial plant of northern and middle United States. The podophyllin resin used in this product is exclusively the American podophyllin (rather than the Indian resin). American podophyllin typically has a reduced level of podophyllotoxin (see below).



What does Podocon 25 look like?



What are the available doses of Podocon 25?

Sorry No records found.

What should I talk to my health care provider before I take Podocon 25?

Sorry No records found

How should I use Podocon 25?

Podocon-25® (25% podophyllin in benzoin tincture) is indicated for the removal of soft genital (venereal) warts (condylomata acuminata) .

PODOCON-25

IS TO BE APPLIED ONLY BY A PHYSICIAN. IT IS NOT TO BE DISPENSED TO THE PATIENT. SHAKE WELL.

sparingly

After treatment time has elapsed, remove dried Podocon-25® with alcohol or soap and water.


What interacts with Podocon 25?

Sorry No Records found


What are the warnings of Podocon 25?

Sorry No Records found


What are the precautions of Podocon 25?

Sorry No Records found


What are the side effects of Podocon 25?

The use of topical podophyllin has been known to result in paresthesia, polyneuritis, paralytic ileus, pyrexia, leukopenia, thrombocytopenia, coma and death .

Pregnancy:

There have been reports of complications associated with the topical use of podophyllin on condylomata of pregnant patients including birth defects, fetal death and stillbirth . In the absence of controlled safety studies, podophyllin remains contraindicated for use on pregnant patients.

Nursing Mothers:

It is not known whether podophyllin is excreted in human milk following topical application. In the absence of controlled safety studies, podophyllin remains contraindicated for use on nursing patients.


What should I look out for while using Podocon 25?

Podocon-25® is contraindicated in diabetics, patients using steroids or with poor blood circulation. Podocon-25® should not be used on bleeding warts, moles, birthmarks or unusual warts with hair growing from them. It is recommended that Podocon- 25® not be used during pregnancy (see Pregnancy warning below).

Podophyllin is a powerful caustic and severe irritant. Keep away from the eyes; if eye contact occurs, flush with copious amounts of warm water and consult physician or poison control center immediately for advice.


What might happen if I take too much Podocon 25?

Sorry No Records found


How should I store and handle Podocon 25?

Store at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAStore at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured and Distributed by:Carlsbad Technology, Inc.Carlsbad, CA 92008 USA Marketed/ Packaged by:GSMS, Inc.Camarillo, CA 93012 USARevised: February 2010CTI-11 Rev. CPrinted in USAPodocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)Podocon-25® is available in 15-mL bottles with tapered tip applicator attached inside cap. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in tight, light-resistant containers.Rx Only1) Blumgarten, A.F.: Text Book of Materia Medica, Pharmacology and Therapeutics; Ed. 7, New York, The Macmillan Company, 1937, pp. 220 and 223.2) Green, L.K., Klima, M., Burns, T.; Arch Dermatol. Vol 124, Nov 1988, p. 1718.3) Martindale, 28th Ed. London, 1982, pp. 1366, 1367.4) Medical Letter; Vol 26, New Rochelle, N.Y., 1984, p10.5) Fisher: Severe Systemic and Local Reactions to Topical Podophyllum Resins; Cutis, Volume 28, 1981.6) Zackheim: Hazards of Topical Mitotic-Blocking Agents; Arch. Dermat. Volume 113, 1977.Manufactured ByPerrigo®Minneapolis, MN 554272124075(05-12)


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Podophyllin is a cytotoxic agent that has been used topically in the treatment of genital warts. It arrests mitosis in metaphase, an effect it shares with other cytotoxic agents such as the vinca alkaloids . The active agent is podophyllotoxin, whose concentration varies with the type of podophyllin used; the American source normally containing one-fourth the amount of podophyllotoxin as the Indian source .

NOTE: PODOCON-25

IS TO BE APPLIED ONLY BY A PHYSICIAN. IT IS NOT TO BE DISPENSED TO THE PATIENT.

Non-Clinical Toxicology
Podocon-25® is contraindicated in diabetics, patients using steroids or with poor blood circulation. Podocon-25® should not be used on bleeding warts, moles, birthmarks or unusual warts with hair growing from them. It is recommended that Podocon- 25® not be used during pregnancy (see Pregnancy warning below).

Podophyllin is a powerful caustic and severe irritant. Keep away from the eyes; if eye contact occurs, flush with copious amounts of warm water and consult physician or poison control center immediately for advice.

The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

Do not use Podocon- 25® if wart or surrounding tissue is inflamed or irritated. Do not use on bleeding warts, moles, birthmarks or unusual warts with hair growing from them.

The use of topical podophyllin has been known to result in paresthesia, polyneuritis, paralytic ileus, pyrexia, leukopenia, thrombocytopenia, coma and death .

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).